Stockreport

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants [Yahoo! Finance]

Anixa Biosciences, Inc.  (ANIX) 
Last anixa biosciences, inc. earnings: 3/9 05:10 pm Check Earnings Report
PDF Combination of Keytruda ® and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination [Read more]